Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

 Full screen view
Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
BT-20
TNBC
Basal A
 AS-252424
PI3K
PI3K
11854.158
uM
24.60350
145.14930
 0.2089 -1.0000 0.6190 0.1259
0.9644
 1.3776
BT-20
TNBC
Basal A
 AS-252424
PI3K
PI3K
10581.141
uM
5.56060
12.73910
 -0.9262 -1.0000 1.3253 0.3251
0.9749
 0.6310
BT-20
TNBC
Basal A
 Baicalein
Lipoxygenase
Metabolism
10581.072
uM
inf
inf
 0.6190 0.6190 0.0000 0.0909
0.5218
 1.0484
BT-20
TNBC
Basal A
 Baicalein
Lipoxygenase
Metabolism
10385.072
uM
66.92780
196.14330
 0.0594 -1.0000 1.0217 0.1865
0.8101
 0.9450
BT-20
TNBC
Basal A
 Baicalein
Lipoxygenase
Metabolism
5904.072
uM
41.61030
43.960
 -0.1564 -0.1579 4.9953 0.0888
0.9910
 1.0242
BT-20
TNBC
Basal A
 Bortezomib
Proteasome
Proteasome
5903.074
uM
0.16496
0.28088
 -0.9339 -0.8906 1.9219 0.9184
0.9950
 1.0729
BT-20
TNBC
Basal A
 Bortezomib
Proteasome
Proteasome
5903.074
uM
0.16496
0.28088
 -0.9339 -0.8906 1.9219 0.9184
0.9950
 1.0729
BT-20
TNBC
Basal A
 Bortezomib
Proteasome
Proteasome
5904.074
uM
0.14054
0.20196
 -0.9625 -0.9253 2.8892 1.0170
0.9965
 0.9654
BT-20
TNBC
Basal A
 Bortezomib
Proteasome
Proteasome
5904.074
uM
0.14054
0.20196
 -0.9625 -0.9253 2.8892 1.0170
0.9965
 0.9654
BT-20
TNBC
Basal A
 Bortezomib
Proteasome
Proteasome
5902.074
uM
0.19709
0.31625
 -0.7789 -0.7635 1.9605 0.8399
0.9972
 1.2939
BT-20
TNBC
Basal A
 Bortezomib
Proteasome
Proteasome
5902.074
uM
0.19709
0.31625
 -0.7789 -0.7635 1.9605 0.8399
0.9972
 1.2939
BT-20
TNBC
Basal A
 Bortezomib
Proteasome
Proteasome
14821.203
uM
0.00839
0.01412
 -0.9630 -0.9614 2.0590 1.2932
0.9998
 1.1544
BT-20
TNBC
Basal A
 Bortezomib
Proteasome
Proteasome
14821.203
uM
0.00839
0.01412
 -0.9630 -0.9614 2.0590 1.2932
0.9998
 1.1544
BT-20
TNBC
Basal A
 Bosutinib
Src
nRTK
11854.145
uM
1.63990
2.68770
 -0.7195 -0.6831 1.7434 0.5148
0.9747
 1.1581
BT-20
TNBC
Basal A
 Bosutinib
Src
nRTK
10581.145
uM
0.82322
1.40790
 -0.7723 -0.7503 1.7079 0.6193
0.9895
 0.9044
BT-20
TNBC
Basal A
 Celecoxib
COX2
COX
10581.136
uM
16.0720
15.08480
 0.1606 0.1358 5.0000 0.3824
0.7296
 0.8342
BT-20
TNBC
Basal A
 Cetuximab
EGFR
ErbB
5903.102
uM
inf
0.01035
 0.7898 0.7837 0.8245 0.0669
0.9137
 1.2557
BT-20
TNBC
Basal A
 Chk2 inhibitor II
CHK2
CHK
10581.14
uM
33.15290
206.59540
 0.2956 -1.0000 0.6005 0.1599
0.8410
 0.9569
BT-20
TNBC
Basal A
 Dactolisib
PI3K
PI3K
10581.146
uM
1.84980
1.48020
 0.1601 0.3360 5.0000 0.2304
0.7895
 1.1650
BT-20
TNBC
Basal A
 Dactolisib
PI3K
PI3K
11854.155
uM
0.17525
0.09792
 0.2170 0.2898 1.4890 0.3258
0.9236
 1.3396
BT-20
TNBC
Basal A
 Dichloroacetate
PDK
PDK
13579.176
uM
inf
inf
 0.8837 0.8837 0.0000 -0.0031
0.4777
 0.7690
BT-20
TNBC
Basal A
 Disulfiram
Proteasome
Proteasome
13579.174
uM
0.07274
0.13130
 -0.9991 -0.6890 1.4667 0.7991
0.9502
 0.8018
BT-20
TNBC
Basal A
 Erlotinib
EGFR
ErbB
5904.092
uM
0.49955
0.93753
 -0.1948 -0.2469 0.6374 0.3467
0.9563
 0.8933
BT-20
TNBC
Basal A
 Erlotinib
EGFR
ErbB
5902.091
uM
20.15740
257.44590
 0.2492 -1.0000 0.4313 0.1682
0.9645
 1.1648
BT-20
TNBC
Basal A
 Erlotinib
EGFR
ErbB
5903.09
uM
1.76560
31.7580
 -0.1899 -1.0000 0.3802 0.3437
0.9914
 0.9291